BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1089 related articles for article (PubMed ID: 19061594)

  • 1. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?
    Roux CH; Brocq O; Leccia N; Giacchero D; Breuil V; Albert C; Lacour J; Perrin C; Euller-Ziegler L
    J Rheumatol; 2007 Feb; 34(2):434-7. PubMed ID: 17295430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab.
    Esser AC; Abril A; Fayne S; Doyle JA
    J Am Acad Dermatol; 2004 May; 50(5 Suppl):S75-7. PubMed ID: 15097933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists.
    Kary S; Worm M; Audring H; Huscher D; Renelt M; Sörensen H; Ständer E; Maass U; Lee H; Sterry W; Burmester GR
    Ann Rheum Dis; 2006 Mar; 65(3):405-7. PubMed ID: 16150791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The appearance of pustular psoriasis during antitumor necrosis factor therapy.
    Goncalves DP; Laurindo I; Scheinberg MA
    J Clin Rheumatol; 2006 Oct; 12(5):262. PubMed ID: 17023816
    [No Abstract]   [Full Text] [Related]  

  • 7. Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy.
    Danko JR; Gilliland WR; Miller RS; Decker CF
    Scand J Infect Dis; 2009; 41(4):252-5. PubMed ID: 19266397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab.
    Fabre S; Gibert C; Lechiche C; Jorgensen C; Sany J
    J Rheumatol; 2005 Dec; 32(12):2432-3. PubMed ID: 16331777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
    Sfikakis PP
    Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptococcal meningitis in a patient treated with infliximab.
    Muñoz P; Giannella M; Valerio M; Soria T; Díaz F; Longo JL; Bouza E
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):443-6. PubMed ID: 17240111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Case report: RAEB in a patient with rheumatoid arthritis treated with methotrexate and infliximab].
    D'Alessandro G; Bianco MR; Politis S; Ferrandina C; Rossi G; Altomare E
    Reumatismo; 2006; 58(1):59-61. PubMed ID: 16639489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases.
    Dereure O; Guillot B; Jorgensen C; Cohen JD; Combes B; Guilhou JJ
    Br J Dermatol; 2004 Aug; 151(2):506-7. PubMed ID: 15327565
    [No Abstract]   [Full Text] [Related]  

  • 14. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review.
    Grinblat B; Scheinberg M
    Semin Arthritis Rheum; 2008 Feb; 37(4):251-5. PubMed ID: 17640718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).
    Bondeson J; Maini RN
    Int J Clin Pract; 2001 Apr; 55(3):211-6. PubMed ID: 11351775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab-induced discoid lupus erythematosus.
    Cemil BC; Atas H; Canpolat F; Akca Y; Sasmaz R
    Lupus; 2013 Apr; 22(5):515-8. PubMed ID: 23554040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab treatment of rheumatoid arthritis.
    Maini SR
    Rheum Dis Clin North Am; 2004 May; 30(2):329-47, vii. PubMed ID: 15172044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha?
    Cuchacovich R; Espinoza CG; Virk Z; Espinoza LR
    J Clin Rheumatol; 2008 Dec; 14(6):353-6. PubMed ID: 19033869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions.
    Lecluse LL; Piskin G; Mekkes JR; Bos JD; de Rie MA
    Br J Dermatol; 2008 Sep; 159(3):527-36. PubMed ID: 18627374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis.
    Jiménez FG; Colmenero JD; Irigoyen MV
    J Infect; 2005 May; 50(4):370-1. PubMed ID: 15845443
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 55.